Continued from page 1

The senators pointed out that the FDA medical officer reported to have been removed from reviewing Avandia “had the most experience with the drug class that includes Avandia.”

Mr. Baucus and Mr. Grassley said they expect FDA Commissioner Andrew von Eschenbach to respond to their concerns by today, in time for the advisory committee meeting.